{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:52:11Z","timestamp":1791989531556,"version":"4.4.0"},"reference-count":102,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS086219"],"award-info":[{"award-number":["R01NS086219"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001543","name":"Children's Cancer Foundation","doi-asserted-by":"publisher","award":["Synodos for NF1"],"award-info":[{"award-number":["Synodos for NF1"]}],"id":[{"id":"10.13039\/100001543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1UG3CA244687"],"award-info":[{"award-number":["1UG3CA244687"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS Research Professor Award"],"award-info":[{"award-number":["ACS Research Professor Award"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Neurofibromatosis Type 1 (NF1) is a common genetic disorder and cancer predisposition syndrome (1:3000 births) caused by mutations in the tumor suppressor gene NF1. NF1 encodes neurofibromin, a negative regulator of the Ras signaling pathway. Individuals with NF1 often develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell linage, some of which progress further to malignant peripheral nerve sheath tumors (MPNSTs). Treatment options for neurofibromas and MPNSTs are extremely limited, relying largely on surgical resection and cytotoxic chemotherapy. Identification of novel therapeutic targets in both benign neurofibromas and MPNSTs is critical for improved patient outcomes and quality of life. Recent clinical trials conducted in patients with NF1 for the treatment of symptomatic plexiform neurofibromas using inhibitors of the mitogen-activated protein kinase (MEK) have shown very promising results. However, MEK inhibitors do not work in all patients and have significant side effects. In addition, preliminary evidence suggests single agent use of MEK inhibitors for MPNST treatment will fail. Here, we describe the preclinical efforts that led to the identification of MEK inhibitors as promising therapeutics for the treatment of NF1-related neoplasia and possible reasons they lack single agent efficacy in the treatment of MPNSTs. In addition, we describe work to find targets other than MEK for treatment of MPNST. These have come from studies of RAS biochemistry, in vitro drug screening, forward genetic screens for Schwann cell tumors, and synthetic lethal screens in cells with oncogenic RAS gene mutations. Lastly, we discuss new approaches to exploit drug screening and synthetic lethality with NF1 loss of function mutations in human Schwann cells using CRISPR\/Cas9 technology.<\/jats:p>","DOI":"10.3390\/genes11050477","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T01:29:15Z","timestamp":1588123755000},"page":"477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors"],"prefix":"10.3390","volume":"11","author":[{"given":"Kyle B.","family":"Williams","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Largaespada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis Primers."},{"key":"ref_2","first-page":"465","article-title":"An Update on Neurofibromatosis Type 1: Not Just Cafe-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer","volume":"107","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/PAP.0000000000000197","article-title":"Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms","volume":"25","author":"Longo","year":"2018","journal-title":"Adv. Anat. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1038\/s41467-018-07452-y","article-title":"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation","volume":"9","author":"Brosseau","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Beert","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/humu.23552","article-title":"Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings","volume":"39","author":"Carrio","year":"2018","journal-title":"Hum. Mutat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant peripheral nerve sheath tumors","volume":"19","author":"Farid","year":"2014","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/neuonc\/nos287","article-title":"Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1","volume":"15","author":"Kolberg","year":"2013","journal-title":"Neuro. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/1479-7364-5-6-623","article-title":"Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis","volume":"5","author":"Thomas","year":"2011","journal-title":"Hum. Genom."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Watson","year":"2014","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fischer-Huchzermeyer, S., Chikobava, L., Stahn, V., Zangarini, M., Berry, P., Veal, G.J., Senner, V., Mautner, V.F., and Harder, A. (2018). Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. BMC Res. Notes., 11.","DOI":"10.1186\/s13104-018-3630-0"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1479-5876-11-213","article-title":"Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors","volume":"11","author":"Peacock","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-3167","article-title":"Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors","volume":"78","author":"Peacock","year":"2018","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57171","DOI":"10.18632\/oncotarget.11036","article-title":"Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors","volume":"7","author":"Ahsan","year":"2016","journal-title":"Oncotarget."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/NEN.0b013e3181c55d55","article-title":"TP53 mutation analysis of malignant peripheral nerve sheath tumors","volume":"69","author":"Verdijk","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14992","DOI":"10.1038\/s41598-017-15183-1","article-title":"The genomic landscape of malignant peripheral nerve sheath tumors: Diverse drivers of Ras pathway activation","volume":"7","author":"Brohl","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.6004\/jnccn.2018.7033","article-title":"Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations","volume":"16","author":"Kaplan","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.3116","article-title":"Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13805","DOI":"10.1074\/jbc.R117.800367","article-title":"Structure, mechanism, and regulation of polycomb repressive complex 2","volume":"293","author":"Moritz","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/modpathol.2016.45","article-title":"Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival","volume":"29","author":"Cleven","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"Beert","year":"2014","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e14713","DOI":"10.7554\/eLife.14713","article-title":"Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain","volume":"5","author":"He","year":"2016","journal-title":"Elife"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/onc.2016.269","article-title":"Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors","volume":"36","author":"Ki","year":"2017","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1038\/s41388-019-0965-5","article-title":"Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors","volume":"38","author":"Ki","year":"2019","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oppel, F., Tao, T., Shi, H., Ross, K.N., Zimmerman, M.W., He, S., Tong, G., Aster, J.C., and Look, A.T. (2019). Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. PLoS Genet., 15.","DOI":"10.1371\/journal.pgen.1008039"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-3-319-30654-4_22","article-title":"Malignant Peripheral Nerve Sheath Tumors","volume":"916","author":"Durbin","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19479","DOI":"10.1073\/pnas.0910398106","article-title":"PTEN dosage is essential for neurofibroma development and malignant transformation","volume":"106","author":"Gregorian","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"620834","DOI":"10.1155\/2012\/620834","article-title":"Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST","volume":"2012","author":"Keng","year":"2012","journal-title":"Sarcoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1523\/JNEUROSCI.23-19-07269.2003","article-title":"Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells","volume":"23","author":"Huijbregts","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ajpath.2012.11.017","article-title":"Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis","volume":"182","author":"Kazmi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0000000000000126","article-title":"Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades","volume":"73","author":"Brosius","year":"2014","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccr.2004.10.016","article-title":"Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis","volume":"7","author":"Ling","year":"2005","journal-title":"Cancer Cell."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.ajpath.2014.04.006","article-title":"Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis","volume":"184","author":"Rahrmann","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1158\/0008-5472.CAN-11-4092","article-title":"PTEN and NF1 Inactivation in Schwann Cells Produces a Severe Phenotype in the Peripheral Nervous System That Promotes the Development and Malignant Progression of Peripheral Nerve Sheath Tumors","volume":"72","author":"Keng","year":"2012","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2013.01.053","article-title":"CXCR4\/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors","volume":"152","author":"Mo","year":"2013","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","article-title":"TORC1 is essential for NF1-associated malignancies","volume":"18","author":"Johannessen","year":"2008","journal-title":"Curr. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/hmg\/ddz095","article-title":"Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation","volume":"28","author":"Rhodes","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e10234","DOI":"10.15252\/emmm.201810234","article-title":"Targeting senescent cells in translational medicine","volume":"11","author":"Doherty","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/ng.2641","article-title":"Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis","volume":"45","author":"Rahrmann","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.celrep.2016.01.074","article-title":"Insertional Mutagenesis Identifies a STAT3\/Arid1b\/beta-catenin Pathway Driving Neurofibroma Initiation","volume":"14","author":"Wu","year":"2016","journal-title":"Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.02.027","article-title":"The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells","volume":"70","author":"Streubel","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1126\/science.286.5447.2176","article-title":"Mouse tumor model for neurofibromatosis type 1","volume":"286","author":"Vogel","year":"1999","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","article-title":"Mouse models of tumor development in neurofibromatosis type 1","volume":"286","author":"Cichowski","year":"1999","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13008","DOI":"10.1073\/pnas.0401236101","article-title":"Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects","volume":"101","author":"Reilly","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/2159-8290.CD-14-0159","article-title":"Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers","volume":"4","author":"Malone","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-17-1789","article-title":"A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies","volume":"77","author":"Maertens","year":"2017","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1158\/2159-8290.CD-17-0177","article-title":"mTOR and HDAC Inhibitors Converge on the TXNIP\/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors","volume":"7","author":"Malone","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI85183","article-title":"Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers","volume":"126","author":"Lock","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1158\/1535-7163.MCT-13-0189","article-title":"NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition","volume":"12","author":"Dodd","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1158\/0008-5472.CAN-16-2643","article-title":"NF1(+\/\u2212) Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response","volume":"77","author":"Dodd","year":"2017","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"15999","DOI":"10.1038\/ncomms15999","article-title":"Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_57","first-page":"1255","article-title":"Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1","volume":"29","author":"Fang","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/TOG.S8830","article-title":"Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy","volume":"5","author":"Sun","year":"2012","journal-title":"Transl Oncogenomics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"608","DOI":"10.15252\/emmm.201404430","article-title":"Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine","volume":"7","author":"Castellsague","year":"2015","journal-title":"Embo Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pollard, K., Banerjee, J., Doan, X., Wang, J., Guo, X., Allaway, R., Langmead, S., Slobogean, B., Meyer, C.F., and Loeb, D.M. A clinically and genomically annotated nerve sheath tumor biospecimen repository. biorxiv, 2020.","DOI":"10.1101\/2019.12.19.871897"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm0195-80","article-title":"Purification and expansion of human Schwann cells in vitro","volume":"1","author":"Rutkowski","year":"1995","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","article-title":"Immortalization of human normal and NF1 neurofibroma Schwann cells","volume":"96","author":"Li","year":"2016","journal-title":"Lab. Invest."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0081","article-title":"Canonical Wnt\/beta-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance","volume":"3","author":"Watson","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.stemcr.2019.01.001","article-title":"Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas","volume":"12","author":"Carrio","year":"2019","journal-title":"Stem. Cell Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","article-title":"Integrating genetic approaches into the discovery of anticancer drugs","volume":"278","author":"Hartwell","year":"1997","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"9","author":"Huang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2017.01.001","article-title":"Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1","volume":"135","author":"Semenova","year":"2017","journal-title":"Biochimie"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"180106","DOI":"10.1038\/sdata.2018.106","article-title":"Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells","volume":"5","author":"Ferrer","year":"2018","journal-title":"Sci. Data"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1200\/JCO.2018.36.15_suppl.10504","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)\u2013associated plexiform neurofibroma: A phase I\/IIa study","volume":"36","author":"McCowage","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Stalnecker, C.A., and Der, C.J. (2020). RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Sci. Signal., 13.","DOI":"10.1126\/scisignal.aay6013"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/MCB.17.2.862","article-title":"Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farnesyl protein transferase","volume":"17","author":"Kim","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4161\/cbt.7.12.6942","article-title":"Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033","volume":"7","author":"Dilworth","year":"2008","journal-title":"Cancer Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.107.135830","article-title":"Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin","volume":"326","author":"Wojtkowiak","year":"2008","journal-title":"J. Pharm. Exp."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2005.03.8638","article-title":"Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas","volume":"24","author":"Widemann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis Clinical Trials Consortium phase II study","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"35753","DOI":"10.18632\/oncotarget.7099","article-title":"Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells","volume":"7","author":"Varin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5784876","DOI":"10.1155\/2020\/5784876","article-title":"Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I\/II Study of Sirolimus in Combination with Ganetespib (SARC023)","volume":"2020","author":"Kim","year":"2020","journal-title":"Sarcoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ccr.2011.08.014","article-title":"Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors","volume":"20","author":"Walton","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7656747","DOI":"10.1155\/2019\/7656747","article-title":"Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)","volume":"2019","author":"Widemann","year":"2019","journal-title":"Sarcoma"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1158\/1078-0432.CCR-13-2576","article-title":"Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs","volume":"20","author":"Patwardhan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/1878-0261.12086","article-title":"Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors","volume":"11","author":"Kolberg","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Kohlmeyer, J.L., Kaemmer, C.A., Pulliam, C., Maharjan, C.K., Moreno Samayoa, A., Major, H.J., Cornick, K.E., Knepper-Adrian, V., Khanna, R., and Sieren, J.C. RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4\/6 inhibitors. Clin. Cancer Res., 2020.","DOI":"10.1158\/1078-0432.CCR-19-2706"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wojcik, J.B., Marchione, D.M., Sidoli, S., Djedid, A., Lisby, A., Majewski, J., and Garcia, B.A. (2019). Epigenomic reordering induced by Polycomb loss drives oncogenesis but leads to therapeutic vulnerabilities in malignant peripheral nerve sheath tumors. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-18-3704"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Frankowski, K.J., Wang, C., Patnaik, S., Schoenen, F.J., Southall, N., Li, D., Teper, Y., Sun, W., Kandela, I., and Hu, D. (2018). Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Sci. Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aap8307"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","article-title":"Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IkappaB and Downregulation of Survivin","volume":"23","author":"Nair","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/pbc.20565","article-title":"Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants","volume":"46","author":"Mahller","year":"2006","journal-title":"Pediatr Blood Cancer."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2353\/ajpath.2008.080376","article-title":"Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes","volume":"173","author":"Farassati","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/neuonc\/not317","article-title":"Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus","volume":"16","author":"Antoszczyk","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_97","first-page":"140","article-title":"Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors","volume":"565","author":"Deyle","year":"2015","journal-title":"Genes"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1541-7786.MCR-15-0427","article-title":"STAT1 and NF-kappaB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells","volume":"14","author":"Jackson","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"17412","DOI":"10.18632\/oncotarget.14885","article-title":"Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation","volume":"8","author":"Currier","year":"2017","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/2326-6066.CIR-18-0014","article-title":"Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy","volume":"6","author":"Ghonime","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet. Oncol."},{"key":"ref_102","first-page":"923","article-title":"Comprehensive pharmacological profiling of neurofibromatosis cell lines","volume":"7","author":"Guo","year":"2017","journal-title":"Am. J. Cancer Res."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/5\/477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:51:29Z","timestamp":1760363489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/5\/477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":102,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["genes11050477"],"URL":"https:\/\/doi.org\/10.3390\/genes11050477","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}